Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baydur, A.
Right arrow Articles by Sharma, O. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baydur, A.
Right arrow Articles by Sharma, O. P.
(Chest. 2001;120:102-108.)
© 2001 American College of Chest Physicians

Respiratory Muscle Strength, Lung Function, and Dyspnea in Patients With Sarcoidosis*

Ahmet Baydur, MD, FCCP; Munif Alsalek, MD; Stan G. Louie, PharmD, PhD and Om P. Sharma, MD, FCCP

* From the School of Medicine and Los Angeles County and University of Southern California Medical Center (Drs. Baydur, Alsalek, and Sharma), Department of Medicine, Division of Pulmonary and Critical Care Medicine, and School of Pharmacy (Dr. Louie), Department of Pharmacy, University of Southern California, Los Angeles, CA.

Correspondence to: Ahmet Baydur, MD, FCCP, GNH 11–900, 2025 Zonal Ave, Los Angeles, CA 90033

Background: Sarcoidosis is a systemic granulomatous disorder that is estimated to involve the skeletal muscles in up to 50% of patients. There is little information on the relationship among respiratory muscle strength, lung volumes, and the degree of dyspnea in patients with sarcoidosis.

Design and patients: Lung function and maximal respiratory muscle force generation were measured in 36 patients with sarcoidosis (24 patients with pulmonary parenchymal infiltration) and 25 control subjects free of cardiorespiratory disease. Dyspnea in the sarcoidosis patients was quantitated by a score based on an activity tolerance assessment scale (ranging from rest to climbing hills or stairs).

Setting: Outpatient clinics of two teaching hospitals.

Results: Mean FVC, maximal voluntary ventilation, total lung capacity (TLC), functional residual capacity, residual volume (RV), and diffusing capacity of the lung for carbon monoxide (DLCO) were all at least 16% less than corresponding control values (in all cases, p < 0.001), while maximal inspiratory mouth pressure (PImax) and maximal expiratory mouth pressure (PEmax) were 37% and 39% less, respectively, than control values (both at p < 0.0001). PImax and PEmax declined with increasing dyspnea in a more graded, steady manner than did spirometric and DLCO values. For all measurements, however, the lowest mean values were found in patients with the most severe level of dyspnea. Strong inverse relationships were observed between PEmax and PImax with dyspnea level (p < 0.0001 and p < 0.01, respectively). Both PImax and PEmax correlated best with absolute values of FVC, while only PEmax correlated with RV (absolute and percent predicted) and percent predicted values of TLC.

Conclusions: Maximal respiratory pressures correlate more closely with dyspnea level than lung volumes and DLCO. Since dyspnea is the most common presentation in early to moderately advanced sarcoidosis, respiratory pressures may be a more reliable index of functional work capacity and reflection of activities of daily living than standard tests of lung function.

Key Words: dyspnea • lung volumes • maximal mouth pressures • respiratory muscles • sarcoidosis




This article has been cited by other articles:


Home page
ChestHome page
R. P. Baughman, B. K. Sparkman, and E. E. Lower
Six-Minute Walk Test and Health Status Assessment in Sarcoidosis
Chest, July 1, 2007; 132(1): 207 - 213.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H.-J. Kabitz, F. Lang, S. Walterspacher, S. Sorichter, J. Muller-Quernheim, and W. Windisch
Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis.
Chest, November 1, 2006; 130(5): 1496 - 1502.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
A. C. White, N. Terrin, K. B. Miller, and H. F. Ryan
Impaired Respiratory and Skeletal Muscle Strength in Patients Prior to Hematopoietic Stem-Cell Transplantation
Chest, July 1, 2005; 128(1): 145 - 152.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
C. E. Cox, J. F. Donohue, C. D. Brown, Y. P. Kataria, and M. A. Judson
The Sarcoidosis Health Questionnaire: A New Measure of Health-related Quality of Life
Am. J. Respir. Crit. Care Med., August 1, 2003; 168(3): 323 - 329.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Chest Physicians.